安杰思跌2.06%，成交额6363.76万元，主力资金净流出1162.17万元

Group 1 - The core viewpoint of the news is that Anjisi's stock has experienced fluctuations, with a recent decline of 2.06% and a total market value of 5.167 billion yuan as of January 16 [1] - Anjisi's stock price has increased by 8.65% since the beginning of the year, with a 1.26% rise over the last five trading days and a 9.64% increase over the last 20 days, while it has decreased by 3.37% over the last 60 days [2] - The company, established on December 6, 2010, specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, with its main revenue sources being GI category (62.74%), EMR/ESD category (23.26%), ERCP category (11.04%), instruments (2.21%), and others (0.74%) [2] Group 2 - As of January 10, 2025, Anjisi had 6,786 shareholders, an increase of 6.58% from the previous period, with an average of 6,124 circulating shares per person, a decrease of 6.17% [2] - For the period from January to September 2025, Anjisi achieved a revenue of 459 million yuan, representing a year-on-year growth of 7.51%, while the net profit attributable to the parent company was 177 million yuan, a decrease of 10.35% year-on-year [2] - Since its A-share listing, Anjisi has distributed a total of 239 million yuan in dividends [3]